observed an increase in Ki‐67+ PD‐1+ CD8+ T cells in the peripheral blood of patients with advanced NSCLC undergoing PD‐1 blockade therapy, with most responses occurring after the first or second treatment cycle.[132] Fairfax et al. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.